ITMI20001107A1 - Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel - Google Patents
Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel Download PDFInfo
- Publication number
- ITMI20001107A1 ITMI20001107A1 IT2000MI001107A ITMI20001107A ITMI20001107A1 IT MI20001107 A1 ITMI20001107 A1 IT MI20001107A1 IT 2000MI001107 A IT2000MI001107 A IT 2000MI001107A IT MI20001107 A ITMI20001107 A IT MI20001107A IT MI20001107 A1 ITMI20001107 A1 IT MI20001107A1
- Authority
- IT
- Italy
- Prior art keywords
- capxol
- treatment
- dispersion
- paclitaxel
- tumor
- Prior art date
Links
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 38
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 8
- 239000011859 microparticle Substances 0.000 title abstract description 6
- 102000009027 Albumins Human genes 0.000 title abstract description 4
- 108010088751 Albumins Proteins 0.000 title abstract description 4
- 239000006185 dispersion Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000001361 intraarterial administration Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 210000001367 artery Anatomy 0.000 claims description 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003090 iliac artery Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000031847 Carcinoma of the anal canal Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000002896 anal canal carcinoma Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (24)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001107A ITMI20001107A1 (it) | 2000-05-18 | 2000-05-18 | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US09/835,384 US6652884B2 (en) | 2000-05-17 | 2001-04-17 | Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel |
| IL14267401A IL142674A0 (en) | 2000-05-18 | 2001-04-18 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
| NZ511201A NZ511201A (en) | 2000-05-18 | 2001-04-19 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
| AU38765/01A AU781517B2 (en) | 2000-05-18 | 2001-04-20 | Method for the treatment of solid tumors by albumin microparticles incorporating Paclitaxel |
| JP2001126061A JP2001354559A (ja) | 2000-05-18 | 2001-04-24 | 固形腫瘍を処置するための薬物を調製するためのアルブミンで安定化されたパクリタキセルの使用およびそれにより得られる薬物 |
| AT01110509T ATE267594T1 (de) | 2000-05-18 | 2001-04-27 | Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel |
| DE60103453T DE60103453T2 (de) | 2000-05-18 | 2001-04-27 | Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel |
| ES01110509T ES2221874T3 (es) | 2000-05-18 | 2001-04-27 | Uso de paclitaxel estabilizado con albumina para preparar un farmaco para el tratamiento de tumores solidos y el farmaco asi obtenido. |
| DK01110509T DK1155692T3 (da) | 2000-05-18 | 2001-04-27 | Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel |
| PT01110509T PT1155692E (pt) | 2000-05-18 | 2001-04-27 | Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido |
| EP01110509A EP1155692B1 (en) | 2000-05-18 | 2001-04-27 | Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
| CA002345482A CA2345482A1 (en) | 2000-05-18 | 2001-04-27 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
| ZA200103755A ZA200103755B (en) | 2000-05-18 | 2001-05-09 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby. |
| TR2001/01353A TR200101353A3 (tr) | 2000-05-18 | 2001-05-15 | Kati tümörlerin tedavisi için bir ilacin hazirlanmasinda albümin ile kararli hale getirilmis paklitaksel kullanimi ve elde edilen ilaç |
| NO20012409A NO330511B1 (no) | 2000-05-18 | 2001-05-16 | Anvendelse av mikropartikler av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, og legemiddel erholdt derved |
| RU2001113688/15A RU2270003C2 (ru) | 2000-05-18 | 2001-05-17 | Лекарственное средство для лечения солидных опухолей на основе паклитаксела, стабилизированного альбумином |
| HU0102039A HU229909B1 (en) | 2000-05-18 | 2001-05-17 | Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby |
| KR1020010026970A KR20010105248A (ko) | 2000-05-18 | 2001-05-17 | 충실성 종양 치료용 약제를 제조하기 위한 알부민안정화된 파클리탁셀의 용도 및 이로부터 수득된 약제 |
| MXPA01004980A MXPA01004980A (es) | 2000-05-18 | 2001-05-17 | Uso de paclitaxel estabilizado con albumina para preparar un medicamento para el tratamiento de tumores solidos y el medicamento obtenido de ese modo. |
| BR0102040-4A BR0102040A (pt) | 2000-05-18 | 2001-05-18 | Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida |
| CNB011192585A CN1198609C (zh) | 2000-05-18 | 2001-05-18 | 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 |
| HK02101781.9A HK1040368B (en) | 2000-05-18 | 2002-03-08 | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby |
| KR1020080094590A KR20080091747A (ko) | 2000-05-18 | 2008-09-26 | 알부민 안정화된 파클리탁셀을 포함하는 고형성 종양 치료용 약물 제형 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001107A ITMI20001107A1 (it) | 2000-05-18 | 2000-05-18 | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITMI20001107A0 ITMI20001107A0 (it) | 2000-05-18 |
| ITMI20001107A1 true ITMI20001107A1 (it) | 2001-11-18 |
Family
ID=11445079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2000MI001107A ITMI20001107A1 (it) | 2000-05-17 | 2000-05-18 | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6652884B2 (enExample) |
| EP (1) | EP1155692B1 (enExample) |
| JP (1) | JP2001354559A (enExample) |
| KR (2) | KR20010105248A (enExample) |
| CN (1) | CN1198609C (enExample) |
| AT (1) | ATE267594T1 (enExample) |
| AU (1) | AU781517B2 (enExample) |
| BR (1) | BR0102040A (enExample) |
| CA (1) | CA2345482A1 (enExample) |
| DE (1) | DE60103453T2 (enExample) |
| DK (1) | DK1155692T3 (enExample) |
| ES (1) | ES2221874T3 (enExample) |
| HU (1) | HU229909B1 (enExample) |
| IL (1) | IL142674A0 (enExample) |
| IT (1) | ITMI20001107A1 (enExample) |
| MX (1) | MXPA01004980A (enExample) |
| NO (1) | NO330511B1 (enExample) |
| NZ (1) | NZ511201A (enExample) |
| PT (1) | PT1155692E (enExample) |
| RU (1) | RU2270003C2 (enExample) |
| TR (1) | TR200101353A3 (enExample) |
| ZA (1) | ZA200103755B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| CN1925874B (zh) * | 2002-12-09 | 2014-12-17 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
| US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2598239C (en) * | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2007069272A2 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| LT2481409T (lt) | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| KR101090505B1 (ko) * | 2008-12-30 | 2011-12-06 | 최은아 | 난담반을 포함하는 암 예방 및 치료용 조성물 |
| AU2010236382B2 (en) | 2009-04-15 | 2016-01-14 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| ES2600912T3 (es) | 2010-03-29 | 2017-02-13 | Abraxis Bioscience, Llc | Métodos para tratar el cáncer |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| WO2011153010A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Biosciences, Llc | Methods of treatment of pancreatic cancer |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| SI2790675T1 (sl) | 2011-12-14 | 2019-11-29 | Abraxis Bioscience Llc | Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| AU2014228386B2 (en) * | 2013-03-13 | 2018-11-29 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| CN110934852A (zh) | 2013-03-14 | 2020-03-31 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CN116585310A (zh) | 2015-06-29 | 2023-08-15 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| CN109906088A (zh) | 2016-08-26 | 2019-06-18 | 奥野哲治 | 微血管血流减少剂及其应用 |
| TWI660728B (zh) | 2018-02-09 | 2019-06-01 | 國立交通大學 | 胺基喹唑啉衍生物及其醫藥組合物與用途 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| CN120919082A (zh) * | 2025-10-16 | 2025-11-11 | 天津医科大学总医院 | 一种负载蛋白药物的GelMA微球、制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| PT693924E (pt) | 1993-02-22 | 2004-09-30 | American Biosciences | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| EP1100494A1 (en) | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin |
-
2000
- 2000-05-18 IT IT2000MI001107A patent/ITMI20001107A1/it unknown
-
2001
- 2001-04-17 US US09/835,384 patent/US6652884B2/en not_active Expired - Lifetime
- 2001-04-18 IL IL14267401A patent/IL142674A0/xx active IP Right Grant
- 2001-04-19 NZ NZ511201A patent/NZ511201A/xx not_active IP Right Cessation
- 2001-04-20 AU AU38765/01A patent/AU781517B2/en not_active Expired
- 2001-04-24 JP JP2001126061A patent/JP2001354559A/ja active Pending
- 2001-04-27 DK DK01110509T patent/DK1155692T3/da active
- 2001-04-27 ES ES01110509T patent/ES2221874T3/es not_active Expired - Lifetime
- 2001-04-27 PT PT01110509T patent/PT1155692E/pt unknown
- 2001-04-27 EP EP01110509A patent/EP1155692B1/en not_active Expired - Lifetime
- 2001-04-27 DE DE60103453T patent/DE60103453T2/de not_active Expired - Lifetime
- 2001-04-27 CA CA002345482A patent/CA2345482A1/en not_active Abandoned
- 2001-04-27 AT AT01110509T patent/ATE267594T1/de active
- 2001-05-09 ZA ZA200103755A patent/ZA200103755B/xx unknown
- 2001-05-15 TR TR2001/01353A patent/TR200101353A3/tr unknown
- 2001-05-16 NO NO20012409A patent/NO330511B1/no not_active IP Right Cessation
- 2001-05-17 RU RU2001113688/15A patent/RU2270003C2/ru active
- 2001-05-17 MX MXPA01004980A patent/MXPA01004980A/es active IP Right Grant
- 2001-05-17 KR KR1020010026970A patent/KR20010105248A/ko not_active Ceased
- 2001-05-17 HU HU0102039A patent/HU229909B1/hu unknown
- 2001-05-18 CN CNB011192585A patent/CN1198609C/zh not_active Ceased
- 2001-05-18 BR BR0102040-4A patent/BR0102040A/pt not_active Application Discontinuation
-
2008
- 2008-09-26 KR KR1020080094590A patent/KR20080091747A/ko not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITMI20001107A1 (it) | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel | |
| KR102265952B1 (ko) | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 | |
| AU2013402794B2 (en) | Cancer treatment with combination of plinabulin and taxane | |
| US20020037917A1 (en) | Treatment of cancer using lipoic acid in combination with ascorbic acid | |
| MX2014007131A (es) | Nanoparticulas que comprenden materiales metalicos y oxido de hafnio, preparacion y usos de los mismos. | |
| WO2019094053A1 (en) | Disulfiram and copper salt dosing regimen | |
| PT1684770E (pt) | Oligo-beta-(1,3)-glucano e anticorpos monoclonais contra o cancro | |
| CN1342096A (zh) | 组胺诱导的协同破坏肿瘤作用 | |
| MXPA04010853A (es) | Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer. | |
| CN115463118A (zh) | 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途 | |
| Tonetti et al. | Use of glutaraldehyde treated autologous human erythrocytes for hepatic targeting of doxorubicin | |
| JP2025015727A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 | |
| RU2123827C1 (ru) | Способ лечения злокачественных опухолей | |
| RU2065307C1 (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени | |
| RU2144835C1 (ru) | Способ лечения лимфом | |
| RU2194541C1 (ru) | Способ комбинированного лечения больных местнораспространенным раком желудка | |
| CN116687833A (zh) | 一种含有抗体偶联白蛋白紫杉醇纳米药物的可溶性微针及其制备方法和应用 | |
| US9717808B2 (en) | Kit for preparation of target radiopharmaceuticals and method of using it | |
| RU2134589C1 (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени | |
| AU2004283011A1 (en) | Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof | |
| KR101221640B1 (ko) | 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도 | |
| CN101856359B (zh) | 一种抗急性髓系白血病的药物组合物 | |
| HK1040368B (en) | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby | |
| CN111840541A (zh) | 聚肌苷酸胞苷酸联合抗cd47抗体在肿瘤治疗中的应用 | |
| CN115414491B (zh) | 一种用于治疗宫颈癌的药物及其制备方法 |